by Dr. C.H. Weaver M.D. 12/2018

Lilly has issued an advanced press release on its SPIRIT-H2H clinical trial, wherein Taltz (ixekizumab) was shown to be more effective than Humira (adalimumab) in a 24 week psoriatic arthritis (PsA) study.

Taltz is a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A) and is currently approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis and psoriatic arthritis.

The SPIRIT-H2H clinical study was designed as a large head-to-head (H2H) clinical trial to assess the effectiveness and safety of Taltz compared to Humira in individuals with active PsA who had not yet been treated with a biologic medication. Overall a total of 566 individuals with PsA were treated with either Taltz or Humira and compared at 24 weeks from initiation of treatment.

The study results were released this week by Lilly the manufacturer of Taltz. Taltz was reported to be superior to Humira in improving both the symptoms of PsA as measured by achieving a reduction in disease activity of at least 50 percent and for improving skin clearance of psoriasis.

Taltz was first approved in the United States in 2016 for treating plaque and the full trial date will be presented in 2019.

Reference:Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis